Cancer Registry Software Market (By Software: Cross disciplinary, Specific; By Deployment Model: On-premise, Cloud-based; By Component: Commercial, Public; By End Use: Government and third party, Private payers, Hospital and medical practice, Pharma biotech and medical device companies, Research institutes; By Functionality) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033
The global cancer registry software market size was valued at USD 59.02 million in 2023 and is expected to surpass around USD 143.62 million by 2033, growing at a CAGR of 9.3% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. cancer registry software market size was estimated at USD 13.92 million in 2023 and is predicted to be worth around USD 35.94 million by 2033, at a CAGR of 9.9% from 2024 to 2033.
North America dominated the cancer registry software market in 2023. The U.S. dominated the cancer registry software market in North America region. The North America region has presence of major market players operating in the cancer registry software market. The cancer registry software market in this region is growing due to the rising prevalence of cancer. In addition, due to high investments in the technology, the demand for cancer registry software is rising on a large scale in North America.
Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. The government of emerging nations such as Japan and China are taking constant efforts for the development of the cancer registry software market. Moreover, the key market players are collaborating with the government agencies for the expansion of the healthcare sector. This factor is driving the growth of the cancer registry software market in Asia-Pacific region.
The Europe cancer registry software market size was calculated at USD 16.00 million in 2023 and is projected to expand around USD 41.08 million by 2033, poised to grow at a CAGR of 9.9% from 2024 to 2033.
| Year | Market Size (USD Million) |
| 2023 | 16.00 |
| 2024 | 17.58 |
| 2025 | 19.33 |
| 2026 | 21.24 |
| 2027 | 23.34 |
| 2028 | 25.65 |
| 2029 | 28.18 |
| 2030 | 30.97 |
| 2031 | 34.02 |
| 2032 | 37.38 |
| 2033 | 41.08 |
The cancer registry software is database or an information system which helps to collect the information regarding cancer patients. One of the key factors driving the growth of the global cancer registry software market is growing incidence of cancer globally. The cancer registry software helps to track and monitor the health of patients who are suffering from cancer. The data collected with the help of cancer registry software helps researchers and healthcare practitioners to develop therapeutics for the treatment of cancer. Thus, the global cancer registry software market is expected to grow in the coming years.
In addition, the growing geriatric population is also driving the growth of the cancer registry software market over the forecast period. The data collected from the cancer registry software helps to control the cancer from spreading all around the world. This software also helps government to track the patients in a particular location and region. As a result, this factor is supporting the growth of the global cancer registry software market.
Another factor boosting the growth of the global cancer registry software market is adoption of advanced technology. The electronic health records are also utilized tremendously for keeping track of the data. Thus, the cancer registry software is being adopted on a large scale across all research centers and healthcare centers. Furthermore, the government of developed and developing countries is taking constant efforts for the growth of the global cancer registry software market during the forecast period.
On the other hand, the data privacy and security are one of the biggest challenges for the growth of the global cancer registry software market. The data and information collected with the help of cancer registry software can be easily hacked and this data can be misused by hackers. Thus, this factor is hindering the cancer registry software market.
| Report Coverage | Details |
| Cancer Registry Software Market Size in 2023 | USD 59.02 Million |
| Cancer Registry Software Market Size by 2033 | USD 143.62 Million |
| Growth Rate from 2024 to 2033 | CAGR of 9.3% |
| Largest Market | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Software, By Deployment Model, By Component, By End User, and By Functionality |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
The standalone segment dominated the cancer registry software market in 2023. The standalone cancer registry software is integrated with latest and advanced features. It is also easy to use and operate. The standalone cancer registry software also helps in the reduction of overhead costs. Thus, all of these factors are propelling the growth of the segment.
The integrated segment is expected to witness strong growth during the forecast period. The integrated cancer registry software helps to collaborate with the hospitals’ software. This software helps to locate patients in any location. The integrated cancer registry software also assists to track and monitor the health of patients.
The on-premise segment dominated the cancer registry software market in 2023. The on-premise cancer registry software is mostly adopted by research institutes who are doing research on cancer. The on-premise cancer registry software is embedded with advanced features which help to store data easily. The on-premise cancer registry software is less risky as compared to other types of models. Thus, the on-premise cancer registry software is widely used in hospitals and research centers.
The cloud-based segment is fastest growing segment of the cancer registry software market in 2023. The cloud-based cancer registry software can be integrated with the real time data and standard guidelines. This software helps in the reduction of information technology overhead costs. In addition, the cloud-based cancer registry software is efficient in nature, which is driving the growth of the segment.
The commercial segment dominated the cancer registry software market in 2023. The data stored in the commercial database is quite safe as compared to public database. The data stored in the commercial database can be easily tracked. The commercial database can be used across research centers and government agencies. Thus, the commercial segment is rising at a rapid pace.
The public segment is fastest growing segment of the cancer registry software market in 2023. The public database is used for the various cancer research programs. The utilization of public database is growing due to the growing number of research centers all over the globe. The public database can help to track patient data from any corner of the world.
The government and third-party segment dominated the cancer registry software market in 2023. The government of established and emerging nations is adopting cancer registry software on the large scale. This software helps to track and monitor cancer patients in their respective region. In addition, the investments made by government for the implementation of cancer registry software in hospitals. This factor is boosting the growth of the global cancer registry software market over the forecast period.
The research institutes segment is fastest growing segment of the cancer registry software market in 2023. The cancer registry software is widely used in research institutes due to growing prevalence of cancer. The growing research and development initiatives by biotechnology and pharmaceutical industry players are also driving the growth of the global cancer registry software market.
Segments Covered in the Report
By Software
By Deployment Model
By Component
By End Use
By Functionality
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Registry Software Market
5.1. COVID-19 Landscape: Cancer Registry Software Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Registry Software Market, By Software Type
8.1. Cancer Registry Software Market, by Software Type, 2024-2033
8.1.1. Cross disciplinary
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Specific
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Cancer Registry Software Market, By Deployment Model Type
9.1. Cancer Registry Software Market, by Deployment Model Type, 2024-2033
9.1.1. On-premise
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Cloud-based
9.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Cancer Registry Software Market, By End Use Type
10.1. Cancer Registry Software Market, by End Use Type, 2024-2033
10.1.1. Government and third party
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Private payers
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Hospital and medical practice
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Pharma biotech and medical device companies
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Research institutes
10.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Cancer Registry Software Market, By Functionality Type
11.1. Cancer Registry Software Market, by Functionality Type, 2024-2033
11.1.1. Cancer Reporting to Meet State & Federal Regulations
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Patient Care Management
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Product Outcome Evaluation
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Medical Research and Clinical Studies
11.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Cancer Registry Software Market, By Component Type
12.1. Cancer Registry Software Market, by Component, 2024-2033
12.1.1. Commercial
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Public
12.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 13. Global Cancer Registry Software Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Software (2021-2033)
13.1.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.1.3. Market Revenue and Forecast, by End Use (2021-2033)
13.1.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.1.5. Market Revenue and Forecast, by Component (2021-2033)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Software (2021-2033)
13.1.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.1.6.3. Market Revenue and Forecast, by End Use (2021-2033)
13.1.6.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.1.7. Market Revenue and Forecast, by Component (2021-2033)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Software (2021-2033)
13.1.8.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.1.8.3. Market Revenue and Forecast, by End Use (2021-2033)
13.1.8.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.1.8.5. Market Revenue and Forecast, by Component (2021-2033)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Software (2021-2033)
13.2.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.2.3. Market Revenue and Forecast, by End Use (2021-2033)
13.2.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.2.5. Market Revenue and Forecast, by Component (2021-2033)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Software (2021-2033)
13.2.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.2.6.3. Market Revenue and Forecast, by End Use (2021-2033)
13.2.7. Market Revenue and Forecast, by Functionality (2021-2033)
13.2.8. Market Revenue and Forecast, by Component (2021-2033)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Software (2021-2033)
13.2.9.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.2.9.3. Market Revenue and Forecast, by End Use (2021-2033)
13.2.10. Market Revenue and Forecast, by Functionality (2021-2033)
13.2.11. Market Revenue and Forecast, by Component (2021-2033)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Software (2021-2033)
13.2.12.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.2.12.3. Market Revenue and Forecast, by End Use (2021-2033)
13.2.12.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.2.13. Market Revenue and Forecast, by Component (2021-2033)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Software (2021-2033)
13.2.14.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.2.14.3. Market Revenue and Forecast, by End Use (2021-2033)
13.2.14.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.2.15. Market Revenue and Forecast, by Component (2021-2033)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Software (2021-2033)
13.3.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.3.3. Market Revenue and Forecast, by End Use (2021-2033)
13.3.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.3.5. Market Revenue and Forecast, by Component (2021-2033)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Software (2021-2033)
13.3.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.3.6.3. Market Revenue and Forecast, by End Use (2021-2033)
13.3.6.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.3.7. Market Revenue and Forecast, by Component (2021-2033)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Software (2021-2033)
13.3.8.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.3.8.3. Market Revenue and Forecast, by End Use (2021-2033)
13.3.8.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.3.9. Market Revenue and Forecast, by Component (2021-2033)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Software (2021-2033)
13.3.10.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.3.10.3. Market Revenue and Forecast, by End Use (2021-2033)
13.3.10.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.3.10.5. Market Revenue and Forecast, by Component (2021-2033)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Software (2021-2033)
13.3.11.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.3.11.3. Market Revenue and Forecast, by End Use (2021-2033)
13.3.11.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.3.11.5. Market Revenue and Forecast, by Component (2021-2033)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Software (2021-2033)
13.4.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.4.3. Market Revenue and Forecast, by End Use (2021-2033)
13.4.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.4.5. Market Revenue and Forecast, by Component (2021-2033)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Software (2021-2033)
13.4.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.4.6.3. Market Revenue and Forecast, by End Use (2021-2033)
13.4.6.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.4.7. Market Revenue and Forecast, by Component (2021-2033)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Software (2021-2033)
13.4.8.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.4.8.3. Market Revenue and Forecast, by End Use (2021-2033)
13.4.8.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.4.9. Market Revenue and Forecast, by Component (2021-2033)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Software (2021-2033)
13.4.10.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.4.10.3. Market Revenue and Forecast, by End Use (2021-2033)
13.4.10.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.4.10.5. Market Revenue and Forecast, by Component (2021-2033)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Software (2021-2033)
13.4.11.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.4.11.3. Market Revenue and Forecast, by End Use (2021-2033)
13.4.11.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.4.11.5. Market Revenue and Forecast, by Component (2021-2033)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Software (2021-2033)
13.5.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.5.3. Market Revenue and Forecast, by End Use (2021-2033)
13.5.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.5.5. Market Revenue and Forecast, by Component (2021-2033)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Software (2021-2033)
13.5.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.5.6.3. Market Revenue and Forecast, by End Use (2021-2033)
13.5.6.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.5.7. Market Revenue and Forecast, by Component (2021-2033)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Software (2021-2033)
13.5.8.2. Market Revenue and Forecast, by Deployment Model (2021-2033)
13.5.8.3. Market Revenue and Forecast, by End Use (2021-2033)
13.5.8.4. Market Revenue and Forecast, by Functionality (2021-2033)
13.5.8.5. Market Revenue and Forecast, by Component (2021-2033)
Chapter 14. Company Profiles
14.1. Rocky Mountain Cancer Data Systems
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. McKesson Corporation
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Onco Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Elekta AB
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. IBM Corporation
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. C/Net Solutions
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Ordinal Data Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Himagine Solutions Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Electronic Registry Systems Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. CONDUENT Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
